Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q2 FY25 results · Jul–Sep 2024
Neuland Laboratories reported revenue from operations of ₹310.84 crore (down 25.6% from Q2 FY24) and net profit of ₹32.84 crore (down 63.2% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 310.84 | 417.75 | −25.6% | 439.60 | −29.3% |
| Other income | 4.33 | 3.05 | +42.1% | 4.81 | −9.9% |
| Total income | 315.18 | 420.80 | −25.1% | 444.41 | −29.1% |
| Profit before tax | 49.42 | 121.59 | −59.4% | 129.84 | −61.9% |
| Net profit for the period | 32.84 | 89.25 | −63.2% | 97.87 | −66.4% |
| EPS, basic (₹) | 25.60 | 69.56 | −63.2% | 76.28 | −66.4% |
| Net margin (%) | 10.6 | 21.4 | 22.3 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 310.84 | 417.75 | −25.6% | 439.60 | −29.3% |
| Other income | 4.33 | 3.05 | +42.1% | 4.81 | −9.9% |
| Total income | 315.18 | 420.80 | −25.1% | 444.41 | −29.1% |
| Profit before tax | 48.54 | 121.40 | −60.0% | 130.31 | −62.8% |
| Net profit for the period | 31.96 | 89.06 | −64.1% | 98.34 | −67.5% |
| EPS, basic (₹) | 24.91 | 69.42 | −64.1% | 76.65 | −67.5% |
| Net margin (%) | 10.3 | 21.3 | 22.4 |
Consolidated
- Filed with BSE
- 06 Nov 2024, 15:20 IST
- Board meeting
- 06 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Nov 2024, 15:20 IST
- Board meeting
- 06 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE